Related references
Note: Only part of the references are listed.Comparison of AbirateroneAcetateVersusKetoconazole in PatientswithMetastaticCastration Resistant Prostate Cancer Refractory to Docetaxel
Avivit Peer et al.
PROSTATE (2014)
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y. Loriot et al.
ANNALS OF ONCOLOGY (2013)
Quantified Pathologic Response Assessed as Residual Tumor Burden Is a Predictor of Recurrence-Free Survival in Patients With Rectal Cancer Who Undergo Resection After Neoadjuvant Chemoradiotherapy
Atin Agarwal et al.
CANCER (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
Lixian Zhong et al.
PLOS ONE (2013)
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
J. Mezynski et al.
ANNALS OF ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: Clinical factors associated with PSA response and disease progression
Daniel Keizman et al.
PROSTATE (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
Mari Nakabayashi et al.
BJU INTERNATIONAL (2010)
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer
C. Serrate et al.
ANNALS OF ONCOLOGY (2009)
Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
Mari Nakabayashi et al.
CANCER (2006)
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583)
EJ Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer
KA Harris et al.
JOURNAL OF UROLOGY (2002)
Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines
RJ Chen et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2000)
Share Paper
